These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

190 related items for PubMed ID: 15940287

  • 1. Case study: management of advanced prostate cancer with soft tissue metastases.
    Kirby R.
    Prostate Cancer Prostatic Dis; 2005; 8(3):290-2. PubMed ID: 15940287
    [No Abstract] [Full Text] [Related]

  • 2. Case study: management of lymph node-positive disease detected at radical prostatectomy.
    Kirby R.
    Prostate Cancer Prostatic Dis; 2005; 8(3):287-9. PubMed ID: 15940288
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Cancer-specific mortality after radiation therapy with short-course hormonal therapy or radical prostatectomy in men with localized, intermediate-risk to high-risk prostate cancer.
    Tsai HK, Chen MH, McLeod DG, Carroll PR, Richie JP, D'Amico AV.
    Cancer; 2006 Dec 01; 107(11):2597-603. PubMed ID: 17039498
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Difficult diagnostic and therapeutic cases: CASE 3. presentation of prostate cancer with cervical adenopathy.
    Gaur S, Aish LS, Oo TH.
    J Clin Oncol; 2004 Mar 01; 22(5):957-8. PubMed ID: 14990654
    [No Abstract] [Full Text] [Related]

  • 7. Prostate cancer tissue is masked by bicalutamide: a case report.
    Ellinger J, Bastian PJ, Biermann K, Schmidt ME, Textor J, Bollmann D, Zhou H, Müller SC.
    Eur J Med Res; 2007 May 29; 12(5):212-5. PubMed ID: 17513193
    [Abstract] [Full Text] [Related]

  • 8. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
    Scholz M, Lam R, Strum S, Jennrich R, Johnson H, Trilling T.
    Urology; 2007 Sep 29; 70(3):506-10. PubMed ID: 17905106
    [Abstract] [Full Text] [Related]

  • 9. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
    Morote J, Orsola A, Planas J, Trilla E, Raventós CX, Cecchini L, Catalán R.
    J Urol; 2007 Oct 29; 178(4 Pt 1):1290-5. PubMed ID: 17698136
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Neoadjuvant hormone therapy with casodex in a dose 150 mg prior to radical prostatectomy in patients with prostatic cancer].
    Rusakov IG, Petrov SB, Alekseev BIa, Veliev EI.
    Urologiia; 2004 Oct 29; (4):15-9. PubMed ID: 15457946
    [No Abstract] [Full Text] [Related]

  • 13. Neuroendocrine differentiation of localized prostate cancer during endocrine therapy.
    Nemoto K, Tomita Y.
    Scand J Urol Nephrol; 2007 Oct 29; 41(6):558-60. PubMed ID: 17853028
    [Abstract] [Full Text] [Related]

  • 14. Gynecomastia and breast pain induced by adjuvant therapy with bicalutamide after radical prostatectomy in patients with prostate cancer: the role of tamoxifen and radiotherapy.
    Di Lorenzo G, Perdonà S, De Placido S, D'Armiento M, Gallo A, Damiano R, Pingitore D, Gallo L, De Sio M, Autorino R.
    J Urol; 2005 Dec 29; 174(6):2197-203. PubMed ID: 16280763
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Solitary peritoneal carcinomatosis in prostate cancer].
    Brehmer B, Makris A, Wellmann A, Jakse G.
    Aktuelle Urol; 2007 Sep 29; 38(5):408-9. PubMed ID: 17907070
    [Abstract] [Full Text] [Related]

  • 17. Side-effects of treatments for locally advanced prostate cancer.
    O'Connor KM, Fitzpatrick JM.
    BJU Int; 2006 Jan 29; 97(1):22-8. PubMed ID: 16336322
    [No Abstract] [Full Text] [Related]

  • 18. Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer.
    Janoff DM, Peterson C, Mongoue-Tchokote S, Peters L, Beer TM, Wersinger EM, Mori M, Garzotto M.
    BJU Int; 2005 Sep 29; 96(4):503-7. PubMed ID: 16104900
    [Abstract] [Full Text] [Related]

  • 19. A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy.
    Davis NB, Ryan CW, Stadler WM, Vogelzang NJ.
    BJU Int; 2005 Oct 29; 96(6):787-90. PubMed ID: 16153201
    [Abstract] [Full Text] [Related]

  • 20. Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy.
    Okegawa T, Kinjo M, Nutahara K, Higashihara E.
    Int J Urol; 2006 Sep 29; 13(9):1197-201. PubMed ID: 16984552
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.